Graphical Abstract Highlights d Gipr is expressed in the hypothalamus, as demonstrated using a new Gipr-Cre mouse model d Gipr cells included somatostatin-positive neurons, glia, and vascular cells d Gipr overlapped partially with Glp1r in human and mouse hypothalamus by RNAscope d Activation of Gipr neurons using local AAV-delivered G q -DREADDs reduced food intake
INTRODUCTION
Glucose-dependent insulinotropic polypeptide (GIP) is a gut hormone released from enteroendocrine cells in the duodenum and jejunum (Buchan et al., 1978; Buffa et al., 1975) within minutes of ingesting a meal (Elliott et al., 1993) . GIP binds its cognate receptor, GIP receptor (GIPR)-a class B G-proteincoupled receptor (GPCR) (Usdin et al., 1993) . GIPR activation stimulates insulin release in pancreatic beta cells (Dupre et al., 1973) , and together with its sister incretin, glucagonlike peptide-1 (GLP-1), GIP is an important glucostat to keep post-prandial blood glucose levels in check. It is GLP-1, however that has enjoyed the therapeutic limelight in efforts to design more effective type 2 diabetes treatments. Initial interest in GIP-based therapies waned following studies showing that the insulinotropic properties of GIP are attenuated in patients with type 2 diabetes (Nauck et al., 1993) . The complex relationship between GIP and adiposity has further obscured our understanding of GIP's therapeutic potential.
Studies showing that genetic or pharmacological blockade of GIPR protects against obesity have implicated GIP in promoting body weight gain (McClean et al., 2007; Miyawaki et al., 2002) . These data are congruent with GIP's role in facilitating triglyceride storage in adipose tissue (Eckel et al., 1979; Wasada et al., 1981) . Though GIPR antagonists have inhibited weight gain in animal models (Boylan et al., 2015; Fulurija et al., 2008; Killion et al., 2018; McClean et al., 2007) , the therapeutic utility of GIPR antagonism in humans is yet to be determined. The recent realization that some peptides designed to be GIPR antagonists exhibit partial agonist activity (Sparre-Ulrich et al., 2015) , confounding the interpretation of some of these studies, as well as evidence indicating that the lipogenic action of GIP may be mediated indirectly via insulin (Campbell et al., 2016; Ugleholdt et al., 2011) , has led some to question the rationale behind blocking
Context and Significance
Several drugs against diabetes and obesity are based on the gut hormone glucagon-like peptide-1 (GLP-1), which controls appetite and blood sugar levels. The related gut hormone glucose-dependent insulinotropic polypeptide (GIP) also controls blood glucose, but its role in food intake is debated. Researchers at the Institute of Metabolic Science in Cambridge, UK identified neurons expressing the GIP receptor in food intake control centers of mouse and human brain. Activating these neurons in mice reduced feeding, providing a neuronal circuit that could underlie the results of recent clinical trials of GLP-1-GIP dual agonist peptides, which suggested that GIP may work together with GLP-1 to suppress appetite. Understanding the role of this neuronal population responsive to GIP will help the development of new drugs targeting diabetes and obesity.
GIP signaling as a route toward tackling obesity (Finan et al., 2016) .
Augmenting GIPR signaling in combination with proven antidiabetic agents has yielded exciting results. In rodents and humans, GLP-1-GIP dual agonism significantly improved glycemic control and provided greater body weight loss compared to treatment with a GLP-1 receptor agonist alone (Coskun et al., 2018; Finan et al., 2013; Frias et al., 2018; Nørregaard et al., 2018) . In mice, this additional weight loss could be attributable to a further reduction in food intake (Coskun et al., 2018; Finan et al., 2013; Nørregaard et al., 2018) . It is tempting to suggest that the addition of GIPR activation underlies the superior performance of these combinatorial therapies (Coskun et al., 2018; DiMarchi, 2018) , although GIPR-only agonists appear to either not or fairly modestly reduce body weight when given in isolation (Coskun et al., 2018; Mroz et al., 2019) . While GLP-1 exhibits central inhibitory actions on food intake (Turton et al., 1996) , comparatively little is known about the central activity of GIP on appetite or the expression profile of Gipr in the CNS. Previous attempts at visualizing the localization of Gipr in the CNS relied on traditional in situ hybridization or radiolabeled ligands (Kaplan and Vigna, 1994; Paratore et al., 2011; Usdin et al., 1993) . While these studies did find evidence of Gipr in the cortex, hippocampus, and olfactory bulb, the low resolution of these methodologies does not allow for the precise mapping of Gipr production to distinct cells.
In this study, we sought to define the central GIP signaling axis and to understand how manipulation of Gipr cells in the brain affects feeding behavior. Through the use of a transgenic mouse, Gipr-Cre, we examined the location, transcriptomic profile, and effects of acute activation of Gipr cells in the CNS.
RESULTS

Gipr Is Expressed in Neurons and Glial Cells in Key
Feeding Centers of the Brain Although two GIPR antagonistic antibodies have been reported (Killion et al., 2018; Ravn et al., 2013) , neither has been used for immunohistochemical localization. To label Gipr cells, we generated a knockin transgenic mouse model (Gipr-Cre) in which Cre-recombinase replaces the Gipr coding sequence, enabling the genetic and chemogenetic manipulation of Gipr cells; mice homozygous for Gipr-Cre are thus Gipr nulls. Gipr null offspring were protected against body weight gain when subjected to a high-fat diet (HFD) for 17 weeks and had significantly lower percent fat mass compared with Gipr-Cre heterozygous and wild-type (WT) littermates (Figures S1A and S1B), supporting previous results from another Gipr knock-out (KO) model (Miyawaki et al., 2002) . Heterozygous Gipr-Cre mice, by contrast, gained a similar amount of weight as WT mice, despite reduced Gipr expression due to haploinsufficiency ( Figure S1C ). For the rest of this study, we used Gipr-Cre heterozygous animals.
By crossing Gipr-Cre mice with ROSA26-EYFP reporter mice (Gipr EYFP ), we identified Gipr cells in target tissues. Staining for EYFP in the pancreas of Gipr EYFP mice reported expression of Gipr in both alpha and beta cells, as expected. Heterogeneous EYFP staining was also found in the surrounding pancreatic exocrine tissue (Figures S1D and S1E). A proportion of adipo-cytes in interscapular brown and inguinal white adipose tissue stained positively for EYFP (Figures S1F and S1G). These data provided confidence that the Gipr-Cre transgene successfully targets Gipr expressing cells, as they are consistent with known expression patterns for Gipr (Campbell and Drucker, 2013) .
To create a map of central Gipr localization, brains of Gipr EYFP mice were serially sectioned and stained for EYFP. In line with in situ and radioligand binding data (Kaplan and Vigna, 1994; Paratore et al., 2011; Usdin et al., 1993) , staining was fairly widespread within the CNS ( Figure S1H ), including key feeding centers of the hypothalamus, such as the arcuate (ARC), paraventricular (PVN), and dorsomedial hypothalamic (DMH) nuclei ( Figure 1A ). Active transcription of Gipr in the adult hypothalamus was confirmed by qPCR ( Figure 1B) .
To create a transcriptomic profile of Gipr cells in the hypothalamus, cell preparations from the hypothalami of Gipr EYFP mice were purified using fluorescence-activated cell sorting (FACS), and their transcriptomes were analyzed via single-cell RNA sequencing (scRNA-seq). Graph-based clustering analysis revealed that hypothalamic Gipr cells separate into six subpopulations ( Figure 1C top). Cluster identities were assigned based on the expression patterns of cell-type-specific genes, including those found in the most enriched cluster markers (Figures 1C [bottom] and 1D, and Table S1), with mural cells (Kcnj8, Abcc9, Mustn1, and Mhy11), ependymocytes (Ccdc153 and Hdc), vascular and leptomeningeal cells (VLMC) (Lum and Pdgfra), oligodendrocytes (Mal and Klk6), and neurons (Snap25 and Syt1) representing distinct clusters of Gipr cells.
As hypothalamic neurons are known to modulate feeding behavior, we analyzed the neuronal cluster in more detail. Gipr neurons expressed markers for both GABAergic (Slc32a1) and glutamatergic (Slc17a6) cells ( Figure 1D ). Genes encoding peptides previously implicated in energy homeostasis, namely Sst, Avp, Tac1, and Cartpt, were among the most highly expressed neurohormonal markers ( Figure 1E ). To examine the heterogeneity of Gipr-fluorescent neurons, we constructed a matrix showing the numbers of individual Gipr cells from the neuronal cluster coexpressing a selection of 20 genes implicated in neuroendocrine signaling pathways ( Figure S2A ). Sst was the primary neuroendocrine marker for Gipr neurons with 83% of Snap25-positive cells in the neuronal cluster expressing Sst. Avp and Pthlh were also expressed in at least half of the Gipr neurons (58% and 50%), with Cartpt and Tac1 expressed in fewer than 50%. Pomc was expressed in less than 10% of Gipr neurons and only at low levels. Consistent with these scRNA-seq results, we observed an apparent enrichment in Sst and diminished Pomc message by qRT-PCR in independently isolated fluorescently labeled Gipr cells ( Figure S2B ).
Local and Peripheral Signals Regulate Gipr Neurons
To identify regulatory cell surface receptors present in Gipr neurons, we analyzed the expression of GPCRs in the neuronal cluster. Grm5 and Gabbr1 were the most highly expressed GPCRs in Gipr neurons, which also expressed ionotropic receptors for glutamate and GABA (Gria2, Gria3, Grin2b, and Gabrb1; data not shown). Other neurotransmitters likely to contribute to Gipr neuron regulation include opioids (via Oprk1 and Oprl1), acetylcholine (via Chrm1 and Chrm3), histamine (Hrh3), and serotonin (Htr1b, Htr1d, and Htr2c). Gipr neurons also expressed receptors for peptide neuroendocrine regulators, including SST (Sstr2 and Sstr1), calcitonin (Calcr), and PACAP (Calcrl) and expressed receptors known to govern energy balance, including Cnr1, Mchr1, Hcrtr2, Tac1r, Ghsr, Cckbr, and Htr2c (Figure 2A ).
The functional activity of several receptors was interrogated at the single-cell level using calcium imaging in cultured hypothalamic neurons from Gipr GCaMP3 mice. The receptors selected were Cckbr, Ghsr, and Htr2c, the expression of which we confirmed by qRT-PCR in additional hypothalamic FACS sorts ( Figure S2C ). Given the finding that some Gipr neurons expressed Cartpt and Pomc, we also examined Lepr, which has previously been shown to induce calcium influx in POMC neurons (Heeley et al., 2018; Smith et al., 2018 ). Of the stimuli tested, glutamate increased calcium in the majority (40/59) of neurons, while only subsets responded to CCK (5/34) and the GHSR agonist hexarelin (7/73). Only 1/15 neurons responded to leptin and no cells responded to 5HT ( Figures 2B and 2C ).
Activation of Hypothalamic Gipr Cells Decreases Food Intake
To assess the effect of acute chemogenetic manipulation of Gipr cell activity on food intake, Gipr-Cre mice received hypothalamic injections of Cre-inducible AAVs expressing the G q -coupled DREADD, hM3D (AAV-hSyn-DIO-hM3D(G q )-mCherry) ( Figure S1 ). (B) Relative expression of Gipr in whole hypothalamic homogenates in WT mice (n = 3). Data are plotted as 2 DCt compared to Actb with the bar representing mean ± SD. (C) Gipr cells were isolated from single-cell digests of hypothalami from two heterozygous Gipr EYFP mice via FACS, and their transcriptomes were analyzed by scRNA-seq followed by clustering analysis. tSNE visualization of hypothalamic Gipr cells indicates that there are six clusters (top). Cell types were assigned according to expression of a combination of marker genes (bottom) (see also Table S1 ). (D) t-SNE plots of the expression of selected markers for neurons (Snap25), GABAergic neurons (Slc32a1), glutamatergic neurons (Slc17a6), oligodendrocytes (Mal), mural cells (Abcc9 and Mustn1), VLMCs (Lum), and ependymocytes (Ccdc153). (E) Violin plots representing expression of genes encoding secreted products within the neuronal cluster. mice ( Figures S3A and S3B ). Food intake effects of Gipr-cell D q activation were assessed in a crossover study ( Figure S3C ). In chow-fed Gipr hypDq mice, activation of D q receptors following injection of clozapine-N-oxide (CNO) significantly suppressed both light-and dark-phase food intake in ad lib-fed and fasted animals ( Figures 3A-3C ). Similarly, CNO injected at the onset of the dark phase in Gipr hypDq mice fed an HFD for 2-4 weeks significantly reduced food intake, but no significant effect was observed when CNO was injected at the start of the light phase . No effect on food intake was observed in control (non-AAV-injected) mice following administration of CNO ( Figure S3D ).
Gipr and Glp1r Are Co-expressed in a Subset of Cells in Humans and Mice To investigate potential overlap between Gipr and GLP-1 receptor (Glp1r) expression, we performed RNAscope analysis of mouse and human hypothalamus. Consistent with the cellular localization identified using Gipr EYFP mice, RNAscope revealed Gipr-positive cells in mouse ARC and DMH. Glp1r-positive cells were also observed in these nuclei, with some cells exhibiting both Gipr and Glp1r expression ( Figures 4A-4C ). In human hypothalamic sections, we similarly observed cells positive for GIPR, GLP1R, or both receptors together (Figures 4D and 4E) . It was noticeable that in both mouse and human, the probes for Glp1r or GLP1R detected a higher density of transcripts per cell than the Gipr or GIPR probes. In mice, this is in accordance with lower expression of Gipr measured by qPCR compared to Glp1r in FACS-purified hypothalamic Gipr cells ( Figure S2C ) as well as homogenates of whole hypothalamus ( Figure S4A ). In human, GIPR signal was also observed in periventricular cells in the ependymal region ( Figure S4B ).
Co-activation of Gipr and Glp1r Cells Does Not Further Reduce Acute Food Intake
To investigate potential additive effects of simultaneously activating hypothalamic Gipr-and Glp1r-positive cells on acute food intake, we first injected AAVs carrying hSyn-DIO-hM3D(G q )-mCherry into the hypothalamus of mice expressing Cre under the control of both the Gipr and Glp1r promoters (Gipr/Glp1r hypDq ) or the Glp1r promoter alone (Glp1r hypDq ). CNO injected at the start of the dark phase significantly reduced 2-h food intake in both fasted Gipr/Glp1r hypDq and Glp1r hypDq mice, although this did not reach statistical significance for the latter ( Figure 4F ). The CNO-dependent reduction in food intake of 52% ± 9% (n = 7) in Gipr/Glp1r hypDq mice was, however, similar in magnitude to the previously observed 50% ± 8% (n = 14) reduction in Gipr hypDq mice ( Figure 3C ). In a second approach, we tested the effect of peripherally administered Exendin-4 (Ex-4) in combination with Gipr cell D q activation on food intake. A sub-maximal dose of Ex-4 was chosen from dose-response trials ( Figure S4C ). While Ex-4, CNO, and the combination of Ex-4 with CNO all reduced 2-h food intake in Gipr hypDq mice, we were unable to detect a significant difference between treatments ( Figure 4G ) on acute food intake.
DISCUSSION
In this study, we generated a new Gipr-Cre mouse model, identifying Gipr-expressing cells in the hypothalamus, and enabling their transcriptomic and functional characterization. We show that (1) Gipr is expressed in neuronal and non-neuronal cell types in key feeding centers of the brain, (2) hypothalamic Gipr neurons express a diverse range of neuroendocrine hormones and hormonal or neurotransmitter receptors, (3) direct activation of hypothalamic Gipr cells potently suppresses food intake, and (4) Gipr is co-expressed with Glp1r in a subset of hypothalamic cells in humans and mice.
Centrally expressed Gipr has previously been implicated in promoting neurogenesis and synaptic plasticity (Faivre et al., 2011; Nyberg et al., 2005; Paratore et al., 2011) . Our finding that Gipr cells are present in the ARC, DMH, and PVH suggests that GIPR signaling may also integrate with well-characterized hypothalamic circuits regulating energy balance (Waterson and Horvath, 2015) . While it could be argued that EYFP or GCaMP3 labeling in Gipr-Cre mice could result in part from lineage tracing, we observed a similar location of Gipr-positive cells using RNAscope. The activation of hSyn-DIO-hM3D(G q )-mCherry in the DREADD experiments provides further proof that Cre, and by implication, Gipr, is actively transcribed in adult hypothalamic cells.
To identify whether Gipr cells could be assigned to known neural networks, we performed scRNA-seq, which revealed substantial heterogeneity of Gipr cells. Although some genes are likely to have exhibited altered expression during the time taken for cell dissociation and separation, the results allowed us to cluster Gipr cells into several populations, including neurons, mural cells, ependymocytes, VLMCs, and oligodendrocytes, each characterized by a distinct profile of marker genes. Gipr neurons near-ubiquitously expressed Sst, with many also expressing Avp and Pthlh and fewer expressing Cartpt, Tac1 and Pomc. The broad expression of Sst in Gipr neurons is striking, and the co-expression of Pthlh in 50% of Gipr neurons suggests that they may predominantly belong to the Pthlh clade of SST neurons identified in recent studies (Campbell et al., 2017) .
Collective stimulation of Gipr cells in the hypothalamus via chemogenetic activation resulted in acute anorexia. While the decrease in food intake upon acute activation of hypothalamic Gipr cells appears to be at odds with the protection of Gipr KO animals from diet-induced obesity, it is likely that the resistance to weight gain exhibited by Gipr KO mice is at least in part due to
Activation of Hypothalamic Gipr-Expressing Cells Decreases Food Intake
Heterozygous Gipr-Cre mice were injected bilaterally with AAV-DIO-hM3D-mCherry into the hypothalamus to produce Gipr hypDq mice. CNO (1 mg/kg) or vehicle was injected i.p. following either ad lib feeding or a 10-h daytime fast before dark-phase food intake or following a 2-h fast for light-phase measurements. These paradigms were tested in both chow-(A)-(C) and HFD-(D)-(F) fed mice. Different symbols (squares and circles) indicate mice from different experimental cohorts (see also Figure S3 ). Dark-phase food intake was compared using a paired t test. Light-phase food intake was compared using a decreased insulin signaling (Campbell et al., 2016) . Indeed, Glp1r KO mice are similarly protected against HFD (Ayala et al., 2010; Hansotia et al., 2007) , and although GLP1R agonists undoubtedly suppress food intake, GLP1R inhibition has been linked to increased energy expenditure under HFD conditions (Krieger et al., 2018) , indicating that incretin hormones have a complex role in regulating appetite and adiposity. Suppression of food intake in Gipr hypDq mice was robust in the dark phase, when appetite-promoting signaling is at its highest in rodents (Yannielli et al., 2007) . Suppression of food intake mediated by hypothalamic Gipr cells would be compatible with expression of established anorexic neuropeptides, in particular AVP and CART (Pei et al., 2014) , (Farzi et al., 2018) , which were expressed in over 40% of Gipr neurons. While it may be tempting to speculate that the melanocortin axis may play a role in Gipr cell-mediated anorexia, Pomc was only expressed in a minority of Gipr neurons and at relatively low levels ( Figure 2E ). Still, it is surprising that the majority of Gipr neurons expressed Sst, as activation of all five Sst-positive neuronal clades (defined by coexpression of Th, Nts, Agrp, Unc13c, or Pthlh) with D q in the ARC has been shown to be orexigenic (Campbell et al., 2017) . By contrast, our results suggest that specific activation of Sstpositive subpopulations expressing Gipr (being Pthlh positive, but Agrp negative) results in anorexia. Although we are not able to link the clear anorexigenic effects seen with D q activation to a defined cell population, the use of hSyn-promoter AAV8 would suggest neuronal targeting (Hammond et al., 2017) , though further experiments are required to determine exactly which Gipr cell types underlie the observed inhibition of food intake.
The synergy between pharmacological GIPR and GLP1R agonism on appetite (Coskun et al., 2018; Finan et al., 2013; Nørregaard et al., 2018) suggests that the GIPR signaling cascade may act to sensitize hypothalamic cells to other anorectic signals. GLP-1 suppresses appetite partly via centrally expressed GLP1R (Secher et al., 2014) . As our RNAscope analysis revealed expression of Gipr and Glp1r in distinct as well as overlapping cell populations in the hypothalamus, the beneficial metabolic effects of GIP and GLP-1 receptor co-activation could arise from synergistic activity of the two receptors on the same cells or from integration of signals downstream of activating different neuronal populations. The lack of a clear additive effect of GLP1R co-activation on acute anorexia downstream of Gipr cell D q activation may suggest that chronic GIPR activation is needed to potentiate the anorexigenic effects of GLP1R agonism. Our identification of Gipr in non-neuronal cells, including cells potentially contributing to the blood brain barrier, raises the possibility that GIPR activation might also alter the accessibility of GLP-1 and other circulating hormones to central nuclei. Future work should address the importance of such mechanisms for chronic GIPR agonist treatments.
In summary, we have characterized previously unrecognized populations of hypothalamic cells that express Gipr in rodents and humans and demonstrated that their acute stimulation potently reduces food intake, identifying the central hypothalamic GIP signaling axis as an additional contributor to the control of energy homeostasis.
Limitations of Study
We report a new Gipr-Cre knockin mouse model to characterize and manipulate hypothalamic cells. While a knockin model is less likely to result in aberrant Cre expression than transgenic models employing randomly integrated constructs in which a gene promoter (often of limited length) drives a transgene, we cannot exclude that some cells might report Cre activity even in the absence of physiologically relevant Gipr expression. This could also result through lineage tracing, where cells are reported that only transiently expressed Gipr, although the finding that DIO-AAVs were activated in the adult hypothalamus indicates ongoing Cre expression, mirroring the detection of Gipr mRNA by RNAscope. We did not observe Ca 2+ responses to GIP in primary cultured neurons, however, GIPR is predominantly G s coupled, and therefore, we would not expect that it's activation would result in increased intracellular calcium levels. Similarly, we do not see acute Ca 2+ elevation in Glp1r-positive neurons in response to GLP-1, which also predominantly activates G s rather than G q signaling. It should also be noted that activation of neurons with D q does not replicate native G s -coupled activation of GIPR. However, transgenic overexpression of GIP elicited a marked reduction in energy intake (Kim et al., 2012) , and ICV administration of GIP reduced food intake (NamKoong et al., 2017) . These data, combined with a recent report using a potent GIPR agonist (Mroz et al., 2019) , demonstrate the potential for native GIPR signaling to impact feeding behavior. Further work should address the differences of G s versus G q activation in Gipr neurons and the role of nonneuronal cells in GIPR signaling in the brain. As we were unable to detect an additive effect of GLP1R and hypothalamic Gipr cell activation on food intake, future work should also address the role of Gipr cells beyond the hypothalamus as well as the metabolic outcomes of chronic rather than acute Gipr cell activation. Figure S4 ). (F) Gipr-Cre x Glp1r-Cre and Glp1r-Cre-only mice were injected bilaterally with AAV-DIO-hM3D-mCherry into the hypothalamus to produce Gipr/Glp1r hypDq and Glp1r hypDq mice, respectively. CNO (1 mg/kg) or vehicle was injected i.p. following a 10-h daytime fast at the onset of the dark phase before measuring food intake 2 h post-activation (see also Figures S3C and S3D ). Food intake was compared using a repeated measures 2-way ANOVA with a Sidak's post-hoc test. **p < 0.01, Gipr/Glp1r hypDq n = 7, Glp1r hypDq n = 4. (G) Heterozygous Gipr-Cre mice were injected bilaterally with AAV-DIO-hM3D-mCherry into the hypothalamus to produce Gipr hypDq mice. Following a 10-h daytime fast Exendin-4 (Ex-4) (1.5 nmol/kg) or saline was injected s.c. 1 h prior to the onset of the dark phase. CNO (0.3 mg/kg) or vehicle was injected i.p. at the onset of the dark phase, food was presented, and food intake measurements were taken 2 h post-activation (see also Figures S3E, S4C, and S4D ). Bars represent mean ± SD. Food intake was compared using a repeated measures 2-way ANOVA with a Sidak's post-hoc test. *p < 0.05, **p < 0.01, Gipr hypDq n = 12.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Frank Reimann (fr222@cam.ac.uk). Gipr-Cre and Glp1r-Cre mice are available for collaborations upon reasonable request and will require an MTA before distribution.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Subjects
Anonymised human hypothalamic tissue samples were provided by the Cambridge Brain Bank. Subjects were approached in life for written consent for brain banking, and all tissue donations were collected and stored following legal and ethical guidelines (NHS reference number 11/0EE/0011). Hypothalamic tissue samples from two individuals were used in RNAscope analysis. Both individuals were female-one aged 95 and one aged 86 at the time of death.
Animals
All animal procedures were approved by the University of Cambridge Animal Welfare and Ethical Review Body and conformed to the Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039). The work was performed under the UK Home Office Project Licenses 70/7824, PE50F6065, and PC02F3663. All mice were group-housed and maintained under SPF health/ immune status in individually ventilated cages with standard bedding and enrichment unless otherwise stated. Mice were housed in a temperature (24 C) and humidity-controlled room on a 12 h light/dark cycle (lights on 6:00, lights out 18:00) with ad libitum access to water and standard laboratory chow diet (13.3% calories from fat, 22.4 % calories from protein, 64.3% calories from carbohydrate, 3.5 kcal/g; Scientific Animal Food Engineering) unless otherwise stated.
Generation of Mouse Models
Gipr-Cre knock-in mice were generated using CRISPR/Cas9 technology. In brief, initially the Gipr-coding sequence from the start codon in exon2 to the stop codon in exon 14 in the bacterial artificial chromosome RP23-384-I23 (Children's Hospital Oakland Research Institute) was replaced with iCre-sequence (a generous gift from Rolf Sprengel, Max Planck Institute for Medical Research, Heidelberg, Germany) using Red/ET recombination technology (Genebridges). From this, a 2754bp sequence containing the iCre sequence flanked by 816bp and 879bp from the Gipr locus was amplified and cloned into pCR-BluntII-TOPO vector to be used as a donor for homologous recombination in C57Bl6/CBA-F1 embryos. One-cell stage fertilized mouse embryos were injected with 15ng/ul circular donor plasmid, 40ng/ul Cas9-protein (ToolGen), 0.61 pmols/ul guide RNAs targeting the wild-type Gipr gene (Dharmacon) and 50uM SCR7 inhibitor (Sigma). Positive recombinants were identified by PCR analysis specific for the recombined allele and correct recombination was confirmed by Sanger sequencing. Likely off-target genetic alterations were also sequenced and excluded, even though mice were subsequently crossed with C57Bl6/JN for >8 generations, which will further remove unwanted genetic modifications. Homozygous Gipr-Cre mice (= Gipr knock-out) were created by crossing heterozygous mice after >8 generations of back-crossing into C57Bl6.
Gipr-Cre mice were crossed with ROSA26-EYFP or ROSA26-GCaMP3 reporter strains to enable fluorescent detection and intracellular calcium level monitoring of cells expressing Gipr by cytosolic EYFP or GCaMP3 expression, respectively (Luche et al., 2007; Zariwala et al., 2012) . Reporter strains were on a mixed C57B6J/N genetic background.
To produce mice expressing Cre in both Gipr and Glp1r expressing cells, Gipr-Cre and Glp1r-Cre (Richards et al., 2014) mice were crossed.
Primary Culture of Hypothalamic Neurons
Primary cultures of hypothalamic neurons were prepared from male and female 4 to 6-week-old Gipr GCaMP3 mice as previously described (Heeley et al., 2018) . For each preparation, tissue isolated from two mice was pooled. Mice were killed by cervical dislocation. Brains were extracted, placed into ice-cold Hibernate-A medium (Thermo Fisher Scientific) containing 0.25% GlutaMAX and 2% B27 (Sigma). The hypothalamus was microdissected and placed in extraction media on ice and cut into 1-mm chunks using a scalpel. Tissue was transferred to Hibernate-A minus calcium medium (BrainBits) containing papain (20 U/ml, Worthington) and 1% GlutaMAX (Sigma) pre-heated at 37 C and digested for 30 min at 37 C under agitation (Thermomixer, 500 rpm). After digestion, tissue extracts from 2 animals were pooled, transferred to a tube containing Hibernate-A with 3.5 U/ml DNase I (Sigma) and triturated using a fire-polished glass pipette. The trituration supernatant was gently loaded on top of a BSA gradient prepared in Hibernate-A medium, spun for 5 min at 300 rcf, and the pellet was resuspended in Neurobasal-A medium containing 0.3 nM FGF-Basic (PeproTech, Rocky Hill, NJ, United States of America), 0.25% GlutaMAX (Sigma), and 2% B27 (Sigma). 100 ml of resuspended cells were plated into cloning cylinders (Sigma) on glass bottom 35 mm dishes (MatTek Corporation), coated with poly-lysine (0.1 mg/ml, Sigma). Plates were placed in an incubator (37 C, 5% CO 2 ) for 1 h. After 1 h, an additional 2 ml culture media was added and the cloning cylinders were removed.
METHOD DETAILS
Body Composition Analysis
Gipr-Cre mice heterozygous for iCre at the Gipr locus were crossed. At 6-7 weeks of age, the resulting male Gipr homozygous, heterozygous, and null offspring were placed on a 45% high fat diet (HFD; 45% calories from fat, 20 % calories from protein, 35% calories from carbohydrate, 4.7 kcal/g; Research Diets Inc.) for 17 weeks. Body weights were recorded twice per week. At the end of 17 weeks on HFD, mice were scanned using a time domain nuclear magnetic resonance (TD-NMR, Bruker Minispec, Bruker Optics, Inc.). The instrument was calibrated for these studies using a quality control check of internal voltages, temperature, magnets, and NMR parameters using a standard provided by the manufacturer.
Immunohistochemistry
Pancreatic and adipose tissues were fixed in 4% paraformaldehyde (PFA), dehydrated in 15% and 30% sucrose and frozen in OCT embedding media (VWR). Cryostat-cut sections (6-10 mm) were mounted directly onto poly-lysine covered glass slides (Thermo Fisher Scientific). Slides were incubated for 1 h in blocking solution containing 5% goat or donkey serum, 0.05% (v/v) Tween-20 and 1% (w/v) BSA. Slides were stained overnight at 4 C with primary antisera in the same blocking solution for proglucagon (1:100, Santa Cruz), insulin (1:100, Abcam), and/or GFP (1:1000, Abcam). Slides were washed with PBS, and incubated with appropriate secondary antisera (donkey or goat AlexaFluors 488 or 555 or 633, Thermo Fisher Scientific) diluted 1:300 for 1 h. Control sections were stained with secondary antisera alone. Sections were mounted with Hydromount (National Diagnostics) prior to confocal microscopy (TCS SP8, Leica).
Brain tissue was collected from perfusion fixed mice. Animals were anaesthetized with Euthatal solution (150 mg/kg in saline) and transcardiacally perfused with PBS followed by 4% PFA. Brains were extracted and post-fixed in 4% PFA, 30% sucrose for 48 h at 4 C. Brains were sectioned using a freezing sliding microtome into 5 subsets of 25 mm sections. For DAB-staining, slices were washed in PBS, then incubated with 0.5% (v/v) hydrogen peroxide for 15 minutes. Slices were washed, then blocked for 1 h in 5% donkey serum, 0.03% (v/v) Tween-20, then incubated with GFP antiserum (1:1000, Abcam) in blocking solution overnight at 4 C. Slices were washed, then incubated in biotinylated donkey anti-goat IgG (1:400, Millipore) in 0.3% (v/v) PBS-Tween20. Sections were incubated with avidin-biotin complex (Vector Laboratories Inc.) and developed using DAB (Abcam). For immunofluorescent staining, slices were washed in PBS, then blocked for 1 h in 5% donkey serum, 0.03% (v/v) Tween-20, then incubated with GFP (1:1000, Abcam) and DsRed antisera (1:1000, Takara Bio) in blocking solution overnight at 4 C. Slices were washed, then incubated with appropriate secondary antisera (AlexaFluors 488 and 555, Thermo Fisher Scientific) diluted 1:300 for 1 h. Sections were then washed, mounted on slides and coverslipped with Vectashield (Vector Laboratories Inc.). Slides were imaged using an Axio Scan.Z1 sliced scanner (Zeiss).
Flow Cytometry
Single cell suspensions were prepared and pooled from the hypothalami of 2-3 Gipr EYFP or Gipr GCaMP3 mice as described previously (Lam et al., 2017) . Briefly, mice were sacrificed by cervical dislocation, and tissue from the hypothalamus located ventrally caudal of the optical nerve chiasm (~Bregma -0.3 to -2.92 mm) was dissected into Hibernate-A medium without calcium (BrainBits). The tissue was digested with 20 U/ml Papain (Worthington) for 30 min at 37 C, followed by trituration in Hibernate-A medium (Thermo Fisher Scientific) containing 0.005% (w/v) DNase 1 (Worthington). The cell suspension was filtered through a 40 mm cell strainer into a fresh tube.
Fluorescence-activated cell sorting was performed using an Influx Cell Sorter (BD Biosciences). Cells were gated according to cell size (FSC), cell granularity (SSC), FSC pulse-width for singlets, fluorescence at 488 nm/532 nm for EYFP and 647/670 nm for nuclear stain with DraQ5 (Biostatus).
Single Cell RNA Sequencing 3500 purified EYFP-positive cells from two 4 to 6-week old female Gipr EYFP mice were purified as described above and pooled for droplet encapsulation. cDNA libraries from purified EYFP-positive cells were generated using the 103 Genomics Chromium Instrument and single-cell expression V2 reagents (10X Genomics). Pooled libraries were sequenced on an Illumina HiSeq 4000 instrument (26-bp first read, 76bp second read), yielding an average of 99000 reads per cell. Library preparation was performed by the Genomics and Transcriptomic Core at the Institute of Metabolic Science. The sequencing was performed at the Genomics Core, Cancer Research UK Cambridge Institute.
Sequencing reads were aligned to the mouse genome (mm10) using CellRanger analysis pipeline V2.0 (103 Genomics). Downstream analyses were performed using the Seurat v2.3.4 R package (Butler et al., 2018) . Cells expressing fewer than 200 unique genes were filtered out from the analysis, leaving 2420 cells.
Gene expression measurements for each cell were normalised using a global-scaling method. 2571 highly variable genes were identified using Seurat with default settings. Dimensionality reduction was performed using principle component analysis (PCA) on these variable genes to identify statistically significant (p<0.05) PCs for downstream clustering analysis. Clustering was performed using the Seurat default graph-based clustering approach. The resultant six clusters were plotted using t-distributed stochastic neighbour embedding (t-SNE).
Marker genes were identified for all clusters using the Mann-Whitney U test, implemented by the FindAllMarkers function in the Seurat v2.3.4 R package. The top 20 gene markers were cross referenced against other bulk and scRNAseq databases (Campbell et al., 2017; Chen et al., 2017; He et al., 2016; Marques et al., 2016) to assign cell type identities for each cluster.
Quantitative RT-PCR For quantitative RT-PCR conducted on purified hypothalamic Gipr-expressing cells, EYFP-or GCaMP3-positive cells were FACSpurified as described above, and collected into RLT lysis buffer (QIAGEN) before being frozen on dry ice. EYFP/GCaMP3-negative cells were also collected. Total RNA was extracted using an RNeasy Plus Micro kit (QIAGEN) according to the manufacturer's protocol. DNAse1 treatment was performed using gDNA spin columns (QIAGEN). RNA was reverse transcribed using the SuperScript III Reverse Transcriptase (Thermo Fisher Scientific).
For quantitative RT-PCR performed on homogenates of whole hypothalamic tissue, total RNA from the hypothalami isolated from 3 Gipr wildtype animals was extracted using an RNeasy Mini kit (QIAGEN) according to the manufacturer's protocol. RNA was treated with DNAse1 (Invitrogen), and reverse transcribed using the SuperScript II Reverse Transcriptase (Thermo Fisher Scientific).
qPCR was performed with a QuantStudio 7 Real-Time PCR system (Applied Biosystems). The PCR reaction mix consisted of firststrand cDNA template, TaqMan TM gene expression primer/probe mix (Thermo Fisher Scientific), and PCR master mix (Thermo Fisher Scientific). Expression of the selected targets was compared to that of Actb measured on the same sample in parallel on the same plate, giving a CT difference (DCT) for Actb minus the test gene. Statistics were performed on the DCT data and only converted to relative expression levels (2 DCT ) for presentation in the figures.
TaqMan TM primers/probes used are listed in the Key Resources Table. Calcium Imaging Imaging experiments were performed using Hamamatsu Orca-ER digital camera (Cairn Research) attached to an Olympus IX71 inverted fluorescent microscope with a 403 oil-immersion objective. Cultured primary hypothalamic cells were imaged 2-16 h after dissociation. Cells were rinsed with standard bath solution (138 mmol/l NaCl, 4.5 mmol/l KCl, 4.2 mmol/l NaHCO 3 , 1.2 mmol/l NaH 2 PO 4 , 2.6 mmol/l CaCl 2 , 1.2 mmol/l MgCl 2 , 10 mmol/l HEPES and 10 mmol/l glucose, pH 7.4) and allowed to equilibrate for 15 min. Gipr cells were identified by their GCaMP3 fluorescence when excited with 488/8 nm and images were taken every 2 seconds using a 75-W xenon arc lamp. Emission was collected using a 510-nm long-pass filter and all images were collected on MetaFluor software (Molecular Devices. Calcium responses to 100 mmol glutamate (Sigma), 100 nmol/l CCK (Tocris), 100 nmol/l hexarelin (LKT Laboratories), 20 mmol/l 5HT (Sigma), and 10 nM leptin (R&D Systems) were recorded as increases in GCaMP3 emission. Responses to 30 mmol/l KCl were used as a positive control.
Recordings were background subtracted and represented as the 488-nm fluorescence intensity. The average GCaMP3 fluorescence intensity was calculated over 10-second time windows for the entirety of the experiment. Responses to test reagents were expressed as fold-changes determined from the peak fluorescence during a 30 second window following the perfusion of the test reagent divided by the average of the baseline taken 30 seconds before and after test reagent application and wash off, respectively. Responses were considered real if they reached a fold defined as those in which the fluorescence change following stimulus addition was at least 1.2 and above-fold.
Viral Injections
All viral brain injections were performed on 8-10 week old male heterozygous Gipr-Cre, Gipr-Cre x Glp1r-Cre, or Glp1r-Cre mice, producing Gipr hypDq , Gipr/Glp1r hypDq , or Glp1r hypDq animals, respectively. Surgical procedures were performed under isofluorane anesthesia, and all animals received Metacam prior to the surgery. Mice were stereotactically implanted with bilateral steel guide cannulae (Plastics One) positioned 1 mm above the ARH (A/P: À1.1 mm, D/V: À4.9 mm, lateral: +0.4 mm from Bregma). Bevelled stainless steel injectors (33 gauge, Plastics One) extending 1 mm from the tip of the guide were used for injections, delivering 500 nl AAV-hSyn-DIO-hM3D(Gq)-mCherry at 75 nl/min (Addgene # 44361-AAV8, 4310 12 vg/mL). Mice were allowed a 2 week recovery period.
Food Intake Measurements
All food intake studies were performed in a crossover manner ( Figure S3 ) on age-matched groups after 1 week recovery and 1 week daily handling acclimatization post-surgery.
For experiments assessing the effect of Gipr D q activation in Gipr hypDq mice, animals were singly housed the day before the experiment. Mice were administered 1 mg/kg clozapine-N-oxide (CNO; Sigma) or an equivalent volume of vehicle containing a matched concentration of DMSO (1%). For light phase activation measurements, mice were injected with either CNO or vehicle at 9:00 following a 2 h fast. Food was weighed 1 h, 2 h, 4 h, 8 h, and 24 h post-injection. For dark phase activation measurements, mice were injected with either CNO or vehicle at 18:00 (start of dark cycle) and food was weighed 2 h later. In dark phase activation measurements on fasted animals, mice were fasted for 10 h prior to the injection. This was a crossover design study, and a full trial was complete after mice had received both CNO and vehicle on each testing regime. At least 3 days elapsed between each injection.
For experiments assessing the effect of Gipr/Glp1r cell co-D q activation, Gipr/Glp1r hypDq and Glp1r hypDq mice were singly housed following surgery. Mice were fasted for 10 h prior to D q activation. Mice were administered 1 mg/kg CNO or an equivalent volume of vehicle containing a matched concentration of DMSO (1%) at 18:00 (start of dark cycle) and food was weighed 2 h later. A full trial was complete after mice had received both CNO and vehicle. At least 3 days elapsed between each injection.
For experiments assessing the effect of Gipr cell D q activation in addition to Exendin-4 (Ex-4) treatment Gipr hypDq mice were singly housed following surgery. Mice were fasted for 10 h prior to D q activation. 1.5 nmol/kg Ex-4 (Tocris) or saline control was administered subcutaneously 1 h prior to the onset of the dark phase. Mice were administered 0.3 mg/kg CNO or an equivalent volume of vehicle containing DMSO (1%) at 18:00 (start of dark cycle) and food was weighed 2 h later. A full trial was complete after mice had received both CNO and vehicle on both the Ex-4 and saline control backgrounds. At least 3 days elapsed between each testing paradigm. Figure S1 : Gipr-Cre mice allow for the manipulation and identification of Gipr-expressing cells in vivo (Related to Figure 1) : A. Gipr-Cre mice heterozygous for Cre at the Gipr locus were crossed producing offspring null, heterozygous, or homozygous for Gipr. Body weight was measured in response to 17 weeks on high fat diet. Significance in weight gain was tested via 2-way ANOVA with a Tukey's post hoc test; 'a' indicates P < 0.05 for Gipr -/vs Gipr +/-, 'b' indicates P < 0.05 Gipr -/vs Gipr +/+ ; n = 7 (Gipr -/-), 8 (Gipr +/-), 10 (Gipr +/+ ). B. After 17 weeks on HFD, body composition was measured via NMR. Significance was determined using one-way ANOVA with a Tukey's post hoc test; n = 7 (Gipr -/-), 8 (Gipr +/-), 10 (Gipr +/+ ). C. Relative expression of iCre and Gipr in whole islets isolated from Gipr +/+ , Gipr +/-, Gipr -/mice (n=3 for each genotype). Data are plotted as 2 ΔCt compared to Actb with bars representing mean +/-SD. Statistical significance was assessed through one-way ANOVA. Pancreas tissue from Gipr EYFP mice was stained for GFP (green) and glucagon (red, D), or insulin (white, E). Inguinal white (F) and interscapular brown (G) adipose tissue from Gipr EYFP mice was stained for GFP (green). H. Coronal sections from heterozygous Gipr EYFP and heterozygous Gipr GCaMP3 mice were stained for GFP. Red circles represent the presence of GFPimmunoreactive somata. Drawings are based on the Paxinos Mouse Brain Atlas with the numerical values in the bottom right corner indicating the A/P location relative to Bregma. Pir, piriform cortex; MPOM, medial preoptic nucleus; SFO, subfornical organ; AD, anterodorsal thalamic nucleus; PVA/PV, paraventricular thalamic nucleus; PaAP/PaPo, paraventricular hypothalamic nucleus; MCPO, magnocellular preoptic nucleus; sChDL, suprachiasmatic nucleus; DG, dentate gyrus; ARC, arcuate nucleus; DM, dorsomedial hypothalamus; IF, interfasicular nucleus; AP, area postrema. Figure 3 and 4F. Each mouse served as its own control. D. Heterozygous Gipr-Cre mice that had not received injections of AAV-DIO-hM3D-mCherry were administered either CNO (1 mg/kg) or vehicle i.p following a 10hr daytime fast in a crossover design study. The amount of food consumed during the beginning of the dark phase was measured 2hr post-injection and compared using a paired t-test. n= 9. E. Illustration of crossover study design used for experiments represented in Figure 4G . Each mouse served as its own control.
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Figure S4: Hypothalamic Gipr localisation; CNO/Ex-4 dose response (Related to Figure 4 ): A. Relative expression of Gipr and Glp1r in whole hypothalamic homogenates in WT mice (n=3). Data are plotted as 2 ΔCt compared to Actb with bars representing mean +/-SD. Expression levels of Gipr and Glp1r were compared using an unpaired student's t test. ***P<0.001; n =3. B. Human hypothalamus tissue samples were labelled for GIPR and GLP1R mRNA using RNAscope. Cells lining the third ventricle (3V), likely to be ependymal cells expressing GIPR. C. Following a 10 h daytime fast heterozygous Gipr-Cre and Gipr WT mice were injected with Ex-4 (1.5, 3, or 10 nmol/kg) or saline s.c. 1hr prior to the onset of the dark phase. At the onset of the dark phase food was presented, and food intake measurements were taken 2hr later. This was a crossover design study where each mouse served as its own control. Food intake was compared using a repeated measures 2-way ANOVA with a Sidak's post hoc test. *P<0.05, ***P<0.001; n = 12. D. Following a 10hr daytime fast Gipr hypDq mice were injected with saline s.c. 1hr prior to the onset of the dark phase. CNO (0.1, 0.3, or 1 mg/kg) or vehicle was injected i.p. at the onset of the dark phase, food was presented, and food intake measurements were taken 2hr post-activation. This was a crossover design study where each mouse served as its own control. Food intake was compared using a repeated measures 2-way ANOVA with a Sidak's post hoc test. *P<0.05; n = 12.
